A. Monnier
University of Franche-Comté
24 Papers
563 Citations
A. Monnier is an academic researcher from University of Franche-Comté. The author has contributed to research in topics: Epirubicin & Breast cancer. The author has an hindex of 11, co-authored 24 publications.
Chat about Author
Papers
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.
601
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
- 01 Jan 2006
TL;DR: Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive breast cancer patients and has a favorable safety profile.
377
Randomized Trial Comparing Six Versus Three Cycles of Epirubicin-Based Adjuvant Chemotherapy in Premenopausal, Node-Positive Breast Cancer Patients: 10-Year Follow-Up Results of the French Adjuvant Study Group 01 Trial
Pierre Fumoleau,Pierre Kerbrat,Pascale Romestaing,Pierre Fargeot,Alain Brémond,Moïse Namer,Simon Schraub,Marie-Jo Goudier,Jeanne Mihura,A. Monnier,Pierre Clavere,Daniel Serin,Philippe Seffert,Christiane Pourny,Thomas Facchini,Jean-Philippe Jacquin,Jean-François Sztermer,Jean Datchary,René Ramos,Elisabeth Luporsi +19 more
TL;DR: After a long-term follow-up in an adjuvant setting, the benefit of six cycles of FEC 50 compared with three cycles, whatever the dose, is highly significant in terms of DFS.
107
Long-Term Cardiac Follow-Up in Relapse-Free Patients After Six Courses of Fluorouracil, Epirubicin, and Cyclophosphamide, With Either 50 or 100 mg of Epirubicin, As Adjuvant Therapy for Node-Positive Breast Cancer: French Adjuvant Study Group
Jacques Bonneterre,Henri Roché,Pierre Kerbrat,Pierre Fumoleau,Marie-Josèphe Goudier,Pierre Fargeot,Philippe Montcuquet,Pierre Clavere,Jean-Claude Barats,A. Monnier,Corinne Veyret,Jean Datchary,Isabelle Van Praagh,Isabelle Chapelle-Marcillac +13 more
TL;DR: In the majority of women with primary breast cancer, the benefits of treatment with FEC 100 in terms of disease-free and overall survival outweigh the risks, and cardiac risk factors should be carefully evaluated in patient selection.
96
Postmenopausal Patients with Node-Positive Resectable Breast Cancer
J. P. Gérard,M. Héry,D. Gedouin,A. Monnier,M. J. Goudier,J. Ph. Jacquin,F. Plat,E. Cabarrot,Daniel Serin,Moïse Namer,P. Fumoleau,P. Hurteloup +11 more
TL;DR: In 1986, the true benefit of adjuvant medical treatment in postmenopausal patients with pathological node-positive breast adenocarcinoma was still controversial as mentioned in this paper, and the French Adjuvant Study Group (FASG) initiated a randomised trial to elucidate the respective roles of chemo-and/or hormonotherapy in this group of patients.
23